Research programme: anti-VEC monoclonal antibodies - Eli Lilly

Drug Profile

Research programme: anti-VEC monoclonal antibodies - Eli Lilly

Alternative Names: Anti-vascular endothelial cadherin monoclonal antibodies-Eli Lilly; E4G10; VE-cadherin MAb

Latest Information Update: 27 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImClone Systems
  • Developer Eli Lilly
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 24 Nov 2008 ImClone Systems has been acquired by Eli Lilly
  • 15 Apr 1999 New profile
  • 15 Apr 1999 Preclinical development for Cancer in Italy (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top